Actively Recruiting
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Led by Chen Xiaoping · Updated on 2025-05-01
160
Participants Needed
2
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.
CONDITIONS
Official Title
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-75.
- No previous local or systemic treatment for hepatocellular carcinoma.
- Child-Pugh liver function score 6le; 7.
- ECOG performance status 0-1.
- No serious organic diseases of the heart, lungs, brain, kidneys, etc.
- Tumor technically resectable by enhanced MRI but with high risk for recurrence (BCLC-A tumor diameter 6ge; 5cm; BCLC-B; BCLC-C); no distant metastasis.
- Pathologic type of hepatocellular carcinoma confirmed by biopsy.
- Multimodal Deep Learning Model screening indicates benefit from HAIC combined with Lenvatinib and PD-1 inhibitors.
You will not qualify if you...
- Pregnant or lactating women.
- Conditions interfering with drug absorption, distribution, metabolism, or clearance (e.g., severe vomiting, chronic diarrhea, intestinal obstruction).
- History of gastrointestinal bleeding within previous 4 weeks or active risk of gastrointestinal bleeding.
- Active infection.
- Other significant clinical or laboratory abnormalities affecting safety.
- Inability to follow study treatment or follow-up schedule.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Huapeng Sun
Xiangyang, Hubei, China, 430000
Actively Recruiting
2
Enyu Liu
Jinan, Shandong, China
Actively Recruiting
Research Team
W
WanGuang Zhang
CONTACT
X
xiaoping Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here